Cancer

In Shocking Reversal, CMS Wants to Allow Medicare Part D Plan Sponsors to Substitute Non-Interchangeable Biosimilars

WASHINGTON, DC / ACCESSWIRE / November 10, 2023 / On November 6, 2023, the Centers for Medicare and Medicaid Services…

5 months ago

Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023

Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and…

5 months ago

Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine

Hamilton, Bermuda, Nov. 10, 2023 (GLOBE NEWSWIRE) -- November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO),…

5 months ago

Cantargia Publishes Interim Report for Third Quarter 2023

LUND, SWEDEN / ACCESSWIRE / November 10, 2023 / Cantargia (STO:CANTA) Cantargia AB's ("Cantargia") interim report for the period January…

5 months ago

OneMedNet Network Expands with New Partnership with Large Academic Research Medical Center to Benefit its Life Science Company Clients

~ Partnership To Leverage Real World Data for Life Science Innovation Accelerating New Diagnostic and Treatment Solutions ~MINNEAPOLIS, MN /…

5 months ago

Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea(TM) DNA Platform

- Preclinical Orders for Additional Customers Underway -STONY BROOK, NY / ACCESSWIRE / November 9, 2023 / Applied DNA Sciences,…

5 months ago

Establishment Labs Announces National Medical Products Administration Approval for Motiva Implants in China

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,…

5 months ago

Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting

TORONTO and HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF),…

5 months ago

SFA Therapeutics Announces Updated Psoriasis Data for SFA-002, Bridge Financing, and Foundational Patent

SFA-002 Updated Extension Data Showing 92% PASI 50 and 72% PASI 75$4.5 Million Bridge Financing led by North South VenturesComposition…

5 months ago